Description

According to a report by StrategyHelix, the global growth hormone deficiency market is set to increase by US$ 1,061.2 million during 2022-2028, growing at a CAGR of 4.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for growth hormone deficiency. The global growth hormone deficiency market is segmented on the basis of brand, route of administration, distribution channel, application, and region. On the basis of brand, the global growth hormone deficiency market has been segmented into Genotropin, Humatrope, Norditropin, Omnitrope, Saizen, others. By route of administration, the global growth hormone deficiency market has been segmented into intramuscular, intravenous, subcutaneous. Based on distribution channel, the global growth hormone deficiency market is categorized into e-commerce, hospital & clinics, pharmacies & drug stores. On the basis of application, the global growth hormone deficiency market has been segmented into adult growth hormone deficiency (AGHD), idiopathic short stature (ISS), pediatric growth hormone deficiency, Prader-Willi syndrome (PWS), small for gestational age (SGA), turner syndrome (TS), others. Geographically, the global growth hormone deficiency market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global growth hormone deficiency market is highly competitive. The leading players in the growth hormone deficiency market include Anhui Anke Biotechnology (Group) Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring B.V., Ipsen S.A., Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the growth hormone deficiency market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Brand: Genotropin, Humatrope, Norditropin, Omnitrope, Saizen, others
Route of administration: intramuscular, intravenous, subcutaneous
Distribution channel: e-commerce, hospital & clinics, pharmacies & drug stores
Application: adult growth hormone deficiency (AGHD), idiopathic short stature (ISS), pediatric growth hormone deficiency, Prader-Willi syndrome (PWS), small for gestational age (SGA), turner syndrome (TS), others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global growth hormone deficiency market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Growth hormone deficiency market overview
Part 3. Market breakdown by brand
– Genotropin
– Humatrope
– Norditropin
– Omnitrope
– Saizen
– Others
Part 4. Market breakdown by route of administration
– Intramuscular
– Intravenous
– Subcutaneous
Part 5. Market breakdown by distribution channel
– E-commerce
– Hospital & clinics
– Pharmacies & drug stores
Part 6. Market breakdown by application
– Adult growth hormone deficiency (AGHD)
– Idiopathic short stature (ISS)
– Pediatric growth hormone deficiency
– Prader-Willi syndrome (PWS)
– Small for gestational age (SGA)
– Turner syndrome (TS)
– Others
Part 7. Market breakdown by region
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)
Part 8. Key companies
– Anhui Anke Biotechnology (Group) Co., Ltd.
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– Ferring B.V.
– Ipsen S.A.
– Merck KGaA
– Novartis AG
– Novo Nordisk A/S
– Pfizer Inc.
– Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.
About StrategyHelix
Disclaimer